{
    "info": {
        "nct_id": "NCT06630221",
        "official_title": "A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations",
        "inclusion_criteria": "* Age ≥ 18 years at the time of signing the informed consent form.\n* Willing and able to adhere to the study visit schedule and other protocol requirements.\n* Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R < 3.5) and < 5% myeloblasts or CMML 0 (CMML-0, for cases with < 2% blasts in PB and < 5% blasts in bone marrow (BM)z,[14] with any one of the notable cytopenias as defined below:\n\n  1. Hgb < 10 g/dL prior to enrollment\n  2. ANC < 1.5×10^9/L\n  3. Platelets < 100×10^9/L\n* Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.\n* TET2 mutation performed at a frequency of at least > 5%.\n* ECOG performance status of 0-2.\n* Adequate organ function, defined as:\n\n  1. Serum total bilirubin < 2x ULN, unless the subject has Gilbert's syndrome. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis. In these cases, approval from the study PI is required.\n  2. Creatinine clearance greater than 30 mL/min based on the Cockroft-Gault glomerular filtration rate estimation.\n  3. Participants being enrolled on study on the basis of anemia, will only be eligible if folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and peripheral smear within normal limits\n  4. Hepatitis panel negative for Hep B and Hep C infection\n  5. Negative for HIV infection\n* Women of childbearing potential (WOCBP) may participate provided they have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 h of starting treatment.\n* WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective contraception (methods that result in < 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose. Males with partners who are WOCBP must agree to use a barrier method.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* High- and Very High-risk MDS (per IPSS-R)\n* CMML 1-2\n* Prior HMA exposure\n* Platelet count > 200×10^9/uL or leukocytosis of at least 25×10⁹/L\n* Marrow fibrosis (any grade)\n* Results of bone marrow biopsy within 1 month of study entry (screening bone marrow biopsy) indicating high-risk MDS or CMML-2.\n* Elevated LFTs (aminotransferases and bilirubin) > 2x ULN\n* Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year) or arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events, unless deemed acceptable by the enrolling treating physician.\n* History of arterial or venous thromboembolism, and on anticoagulation.\n* Severe hepatic impairment (Child-Pugh Class C)\n* Recent history of cancer (i.e., within the past 5 years) with > 50% chance of cancer recurrence in the next 5 years\n* Current or prior history of hematologic malignancy\n* Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.\n* Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.)\n* Positive direct Coombs test\n* Evidence of hypersplenism on physical exam\n* Pregnant or lactating (women)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate organ function, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0-2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Creatinine clearance greater than 30 mL/min based on the Cockroft-Gault glomerular filtration rate estimation.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance greater than 30 mL/min based on the Cockroft-Gault glomerular filtration rate estimation.",
                    "criterion": "creatinine clearance (Cockroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* TET2 mutation performed at a frequency of at least > 5%.",
            "criterions": [
                {
                    "exact_snippets": "TET2 mutation performed at a frequency of at least > 5%",
                    "criterion": "TET2 mutation",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years at the time of signing the informed consent form.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years at the time of signing the informed consent form.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Hgb < 10 g/dL prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Hgb < 10 g/dL prior to enrollment",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. ANC < 1.5×10^9/L",
            "criterions": [
                {
                    "exact_snippets": "ANC < 1.5×10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Hepatitis panel negative for Hep B and Hep C infection",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis panel negative for Hep B",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis panel negative for ... Hep C infection",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Negative for HIV infection",
            "criterions": [
                {
                    "exact_snippets": "Negative for HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) may participate provided they have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 h of starting treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum pregnancy test at screening",
                    "criterion": "serum pregnancy test at screening",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum or urine pregnancy test within 72 h of starting treatment",
                    "criterion": "serum or urine pregnancy test within 72 h of starting treatment",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 72 h of starting treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Platelets < 100×10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Platelets < 100×10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participants being enrolled on study on the basis of anemia, will only be eligible if folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and peripheral smear within normal limits",
            "criterions": [
                {
                    "exact_snippets": "folate ... within normal limits",
                    "criterion": "folate level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "B12 ... within normal limits",
                    "criterion": "B12 level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum iron ... within normal limits",
                    "criterion": "serum iron level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum ferritin ... within normal limits",
                    "criterion": "serum ferritin level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "total iron binding capacity ... within normal limits",
                    "criterion": "total iron binding capacity",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "haptoglobin ... within normal limits",
                    "criterion": "haptoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "peripheral smear within normal limits",
                    "criterion": "peripheral smear",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective contraception (methods that result in < 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose. Males with partners who are WOCBP must agree to use a barrier method.",
            "criterions": [
                {
                    "exact_snippets": "WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective contraception (methods that result in < 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose.",
                    "criterion": "sexual activity/contraception agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain from sexual intercourse or use effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% pregnancy rate"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during eltrombopag therapy and for at least 7 days after the last eltrombopag dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Males with partners who are WOCBP must agree to use a barrier method.",
                    "criterion": "barrier contraception method agreement (males with partners who are WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use barrier method",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum total bilirubin < 2x ULN, unless the subject has Gilbert's syndrome. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis. In these cases, approval from the study PI is required.",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin < 2x ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the subject has Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Higher levels are acceptable if these can be attributed to ineffective erythropoiesis",
                    "criterion": "ineffective erythropoiesis",
                    "requirements": [
                        {
                            "requirement_type": "attribution of elevated bilirubin",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "approval from the study PI is required",
                    "criterion": "study PI approval",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R < 3.5) and < 5% myeloblasts or CMML 0 (CMML-0, for cases with < 2% blasts in PB and < 5% blasts in bone marrow (BM)z,[14] with any one of the notable cytopenias as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R < 3.5)",
                    "criterion": "myelodysplastic syndrome (MDS) risk category",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "very low-risk MDS",
                                "low-risk MDS",
                                "intermediate-risk MDS"
                            ]
                        },
                        {
                            "requirement_type": "IPSS-R score",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "< 5% myeloblasts",
                    "criterion": "myeloblast percentage",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CMML 0 (CMML-0, for cases with < 2% blasts in PB and < 5% blasts in bone marrow (BM)",
                    "criterion": "chronic myelomonocytic leukemia (CMML) subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "CMML-0"
                        },
                        {
                            "requirement_type": "peripheral blood blast percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "bone marrow blast percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with any one of the notable cytopenias as defined below",
                    "criterion": "notable cytopenias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.",
            "criterions": [
                {
                    "exact_snippets": "Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine)",
                    "criterion": "response to prior MDS therapies",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "relapsed",
                                "refractory",
                                "resistant",
                                "intolerant",
                                "inadequate response"
                            ]
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "EPOs",
                                "luspatercept",
                                "HMAs",
                                "azacytidine",
                                "decitabine"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with del (5q) must have failed prior lenalidomide therapy",
                    "criterion": "response to lenalidomide therapy in patients with del (5q)",
                    "requirements": [
                        {
                            "requirement_type": "genetic subtype",
                            "expected_value": "del (5q)"
                        },
                        {
                            "requirement_type": "response",
                            "expected_value": "failed prior lenalidomide therapy"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.",
            "criterions": [
                {
                    "exact_snippets": "Known dysphagia",
                    "criterion": "dysphagia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "short-gut syndrome",
                    "criterion": "short-gut syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastroparesis",
                    "criterion": "gastroparesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally",
                    "criterion": "conditions limiting oral drug ingestion or gastrointestinal absorption",
                    "requirements": [
                        {
                            "requirement_type": "effect",
                            "expected_value": "limits ingestion or gastrointestinal absorption of orally administered drugs"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating (women)",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating (women)",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or prior history of hematologic malignancy",
            "criterions": [
                {
                    "exact_snippets": "Current or prior history of hematologic malignancy",
                    "criterion": "hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Marrow fibrosis (any grade)",
            "criterions": [
                {
                    "exact_snippets": "Marrow fibrosis (any grade)",
                    "criterion": "marrow fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of hypersplenism on physical exam",
            "criterions": [
                {
                    "exact_snippets": "Evidence of hypersplenism on physical exam",
                    "criterion": "hypersplenism",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_physical_exam",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior HMA exposure",
            "criterions": [
                {
                    "exact_snippets": "Prior HMA exposure",
                    "criterion": "HMA (hypomethylating agent) exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe hepatic impairment (Child-Pugh Class C)",
            "criterions": [
                {
                    "exact_snippets": "Severe hepatic impairment (Child-Pugh Class C)",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "Child-Pugh class",
                            "expected_value": "C"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of arterial or venous thromboembolism, and on anticoagulation.",
            "criterions": [
                {
                    "exact_snippets": "History of arterial or venous thromboembolism",
                    "criterion": "thromboembolism (arterial or venous)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on anticoagulation",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High- and Very High-risk MDS (per IPSS-R)",
            "criterions": [
                {
                    "exact_snippets": "High- and Very High-risk MDS (per IPSS-R)",
                    "criterion": "myelodysplastic syndromes (MDS) risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category (per IPSS-R)",
                            "expected_value": [
                                "High",
                                "Very High"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count > 200×10^9/uL or leukocytosis of at least 25×10⁹/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count > 200×10^9/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 200,
                                "unit": "×10^9/uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "leukocytosis of at least 25×10⁹/L",
                    "criterion": "leukocytosis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "×10⁹/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive direct Coombs test",
            "criterions": [
                {
                    "exact_snippets": "Positive direct Coombs test",
                    "criterion": "direct Coombs test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CMML 1-2",
            "criterions": [
                {
                    "exact_snippets": "CMML 1-2",
                    "criterion": "chronic myelomonocytic leukemia (CMML) subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "CMML-1",
                                "CMML-2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Results of bone marrow biopsy within 1 month of study entry (screening bone marrow biopsy) indicating high-risk MDS or CMML-2.",
            "criterions": [
                {
                    "exact_snippets": "Results of bone marrow biopsy within 1 month of study entry",
                    "criterion": "bone marrow biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since test",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "indicating high-risk MDS or CMML-2",
                    "criterion": "bone marrow biopsy result",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "high-risk MDS",
                                "CMML-2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Elevated LFTs (aminotransferases and bilirubin) > 2x ULN",
            "criterions": [
                {
                    "exact_snippets": "Elevated LFTs (aminotransferases ... > 2x ULN",
                    "criterion": "aminotransferases",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Elevated LFTs (aminotransferases and bilirubin) ... > 2x ULN",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent history of cancer (i.e., within the past 5 years) with > 50% chance of cancer recurrence in the next 5 years",
            "criterions": [
                {
                    "exact_snippets": "Recent history of cancer (i.e., within the past 5 years)",
                    "criterion": "history of cancer",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "> 50% chance of cancer recurrence in the next 5 years",
                    "criterion": "chance of cancer recurrence",
                    "requirements": [
                        {
                            "requirement_type": "probability",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.)",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.)",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        },
                        {
                            "requirement_type": "systemic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "persistence_of_signs_or_symptoms",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "lack_of_improvement_with_treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year) or arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events, unless deemed acceptable by the enrolling treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year)",
                    "criterion": "pre-existing cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known coronary artery disease with percutaneous intervention",
                    "criterion": "coronary artery disease with percutaneous intervention",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke within the last year",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events",
                    "criterion": "arrhythmia associated with increased risk of thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless deemed acceptable by the enrolling treating physician",
                    "criterion": "physician override for cardiovascular or arrhythmia exclusion",
                    "requirements": [
                        {
                            "requirement_type": "physician approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Willing and able to adhere to the study visit schedule and other protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to adhere to the study visit schedule",
                    "criterion": "willingness to adhere to study visit schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to adhere to the study visit schedule",
                    "criterion": "ability to adhere to study visit schedule",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to adhere to ... other protocol requirements",
                    "criterion": "willingness and ability to adhere to other protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}